ALKERMES | ALKS - Коммерческие и административные расходы





Коммерческие и административные расходы Изменить Дата
AbbVie USD 3.84B 205M 2026-09
Acadia Pharmaceuticals USD 146.88M 1.69M 2026-09
ALKERMES USD 190.54M 6.1M 2026-09
Amgen USD 1.68B 40M 2026-09
Biogen USD 752M 42.3M 2026-09
BioMarin Pharmaceutical USD 333.64M 61.91M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
Heron Therapeutics USD 23.74M 605K 2025-12
Ionis Pharmaceuticals USD 154M 23.92M 2026-09
J&J USD 6.25B 168M 2026-09
Malin Corporation EUR 1.1M 400K 2024-12
Merck USD 2.86B 25M 2026-09
Minerva Neurosciences USD 2.48M 58.79K 2024-09
Nektar Therapeutics USD 11.87M 1.7M 2026-03
Neurocrine Biosciences USD 366.3M 16.8M 2026-09
Otsuka Holdings JPY 281.85B 7.41B 2026-09
Ovoca Bio EUR 617K 15K 2025-12
Pfizer USD 3.28B 132M 2026-09
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Vertex Pharmaceuticals USD 556.3M 25.9M 2026-09